Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Improved SLE/LN Disease Activity Measures and Biomarkers in Patients with Highly Active Non-Renal SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study